Mayne Pharma Group (MYX) ASX Small Caps Conference 2026 summary

Business performance and transformation

• Lost 75% of market value after a failed takeover, but operations remained resilient with positive first-half results and net cash position.

• Revenue for FY2025 is AUD 408 million, with 50% generated in the first half; three business units: Women's Health, Dermatology, and International.

• Shifted from generics to branded pharma, increasing branded revenue share from 68% in FY2024 to 84% in H1 FY2026, raising gross margins from 56% to 65%.

• Women's Health is the largest and fastest-growing segment, with four branded products holding low but growing U.S. market shares.

• Dermatology expanded with acquisition of TWYNEO and EPSOLAY, both high-margin products with patent protection through 2042.

Strategic initiatives and innovation

• Developed DistributeRx™, a wholly owned subsidiary launched this month, to simplify U.S. pharma distribution and improve patient access.

• DistributeRx™ includes a digital ecosystem for price transparency and a cash pharmacy licensed in all 50 states.

• Focus for FY2026 is on growing Women's Health market share, advancing disintermediation in Dermatology, and expanding international out-licensing.

• Major capital investment of AUD 18 million in the Salisbury facility to support international growth and out-licensing.

• Company is generating free cash flow and considering capital deployment options, including a share buyback.

Market positioning and outlook

• Trades at a fraction of U.S. specialty pharma peers, roughly one-fifth to one-tenth of their multiples.

• None of the products are susceptible to disruption from GLP-1s; some products may benefit from increased demand.

• Key growth drivers for the next 12–24 months: DistributeRx™ rollout, increased menopause therapy adoption after black box warning removal, and under-penetrated branded assets.

• BIJUVA, a menopause asset, is the fastest-growing promoted product with significant future growth potential.

• Lessons from the failed takeover include the importance of protecting company value, culture, and thorough due diligence on potential acquirers.